Post-market Safety Profile of the VARIPULSE™ Pulsed Field Ablation Catheter Before and After the FDA Recall: Insights from the FDA MAUDE Database

Heart rhythm disorders are a common challenge in modern medicine, with atrial fibrillation being the most frequent type. This condition causes the heart's upper chambers to quiver instead of beating steadily, which significantly increases the risk of stroke and heart failure. For decades, doctors have treated this by using heat or cold to scar tiny areas of heart tissue, effectively resetting the rhythm. However, these traditional methods carry a risk of damaging nearby healthy structures, such as the esophagus or nerves, because the energy used is not perfectly selective. A newer approach, known as pulsed field ablation, has emerged as a potential solution. Instead of heat or cold, this technique uses rapid bursts of electricity to create tiny holes in the cell membranes of heart muscle cells, causing them to die while largely sparing the surrounding tissues. It is a more precise tool, designed to fix the rhythm without the collateral damage of older methods.

In late 2024, the United States Food and Drug Administration approved a specific system for this new technology called VARIPULSE. It combines a flexible catheter, a power generator, and a mapping system to guide doctors through the procedure. Shortly after it became available for widespread use, a safety concern arose. Reports began to surface suggesting that patients were experiencing strokes or transient ischemic attacks at a higher rate than seen in the initial clinical trials. In response, the FDA issued a temporary correction in early 2025, updating the instructions for doctors to focus only on specific areas of the heart and to avoid certain techniques, but the device was not removed from the market. To understand what was truly happening in the real world, a team of researchers turned to a vast public database that tracks medical device issues. They wanted to see if the safety concerns were widespread, what specific problems were occurring, and whether the situation improved after the FDA's intervention.

The researchers analyzed nearly 380 reports submitted to the FDA between November 2024 and April 2026. These reports came from hospitals and manufacturers who are required to log any adverse events or device malfunctions. The goal was not to calculate the exact percentage of patients who had problems, but to understand the nature of the issues that were being reported. The data revealed that the vast majority of reports involved injuries to patients rather than the device simply breaking on its own. While the device itself functioned correctly in most cases, the interaction between the tool and the patient led to complications. The most common serious events reported were strokes or cerebrovascular accidents, followed by cardiac tamponade, a condition where fluid builds up around the heart and restricts its ability to pump.

Among the specific mechanical issues, the most frequent problem was a jam where the catheter would get stuck or fail to move smoothly within the heart. Another notable issue was the formation of small blood clots on the device during the procedure. These physical findings align with the clinical observations of strokes, suggesting that the movement of the catheter or the formation of clots might be contributing to the risk of embolism. The study also looked at the five deaths recorded in the database. In every case, the manufacturers concluded that the device itself did not directly cause the death. The causes were varied, including hemorrhagic strokes and heart failure, often linked to the complex health conditions of the patients rather than a failure of the machine.

A key part of the investigation was comparing the reports before and after the FDA's corrective action in February 2025. The researchers found that the proportion of reports involving stroke or related brain events remained remarkably similar before and after the new instructions were issued. Before the correction, these events made up nearly half of all reports, and they continued to make up a similar share afterward. This stability suggests that while the FDA's guidance was important, the underlying risk of these specific complications did not vanish immediately. The authors emphasize that this does not mean the device is unsafe, but rather that the procedure requires careful handling and that doctors are still navigating the learning curve associated with this new technology.

The study concludes that while the VARIPULSE system shows a low rate of death, it is accompanied by a notable number of reports regarding strokes and mechanical handling issues. The data indicates that the problems are less about the device failing to work and more about the complexity of using it inside a beating heart. The researchers suggest that continued monitoring is essential. As more doctors gain experience with pulsed field ablation, and as the technology continues to evolve, the hope is that these complications can be minimized. The findings serve as a reminder that even with advanced, selective tools, the human element of the procedure and the patient's own health factors play a critical role in the final outcome.